title: [Risk factors management in 5708 ambulatory patients suffering from peripheral vascular disease followed in urban practices].
abstract: OBJECTIVE
  we examined the management of risk factors in patients suffering from obliterating peripheral arterial disease (OPAD), in urban medical practice.
  
  
  METHODS
  PRISMA, ECLAT1 and APRES are surveys based on urban medicine in France. These 3 studies have allowed a compilation of data pertaining to the control of risk factors in patients suffering from one or more clinical manifestations of atherothrombosis, including cerebral vascular accident, coronary insufficiency or OPAD. The study population was divided among patients with isolated OPAD, versus OPAD associated with coronary artery disease (CAD), versus OPAD associated with cerebral vascular disease.
  
  
  RESULTS
  a total of 5 708 patients with stable OPAD were included among the 3 studies. Risk factors were not managed in the majority of patients, including 62.6% of hypercholesterolemic patients, 71.1% of diabetics, and 77.4% of hypertensive patients. Overall, the control of risk factors was less satisfactory in patients with OPAD than in patients with CAD. Smoking (70.6% current or past smokers) remains a major risk factor in OPAD. The proportion of current smokers was significantly higher is the group with isolated OPAD than in the other 2 groups of patients (p < 0.0001).
  
  
  CONCLUSIONS
  The control of risk factors in patients with OPAD is suboptimal, mainly because of failure to reach the therapeutic goals, rather than because of poor medical management. It is important that recent recommendations be implemented in medical practice. Awareness of the primary physicians will be key in the optimisation of treatment prescriptions and, above all, in the achievement of a higher level of clinical performance.
authors.affiliation: Service de médecine vasculaire, CHU Rangueil, Toulouse.
authors.forename: M
authors.initials: M
authors.lastname: Dedola
authors.forename: E
authors.initials: E
authors.lastname: Godoi
authors.forename: G
authors.initials: G
authors.lastname: Coppé
authors.forename: J P
authors.initials: JP
authors.lastname: Cambou
authors.forename: C
authors.initials: C
authors.lastname: Cantet
authors.forename: J L
authors.initials: JL
authors.lastname: Mas
authors.forename: M
authors.initials: M
authors.lastname: Guérillot
authors.forename: A
authors.initials: A
authors.lastname: Vahanian
authors.forename: M A
authors.initials: MA
authors.lastname: Herrman
authors.forename: G
authors.initials: G
authors.lastname: Jullien
authors.forename: A
authors.initials: A
authors.lastname: Leizorovicz
authors.forename: H
authors.initials: H
authors.lastname: Boccalon
mesh_terms: D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D001157:Arterial Occlusive Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D005602:France / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D015995:Prevalence; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D000074606:Smoking Prevention; D014505:Urban Population / Q000706:statistics & numerical data